Keisuke Hirai, PhD, Osaka University - Publications

Affiliations: 
Takeda Chemical Industries 
Area:
Neurodegenerative diseases

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Nishiyama K, Hirai K. In vitro comparison of duration of action of melatonin agonists on melatonin MT1 receptor: possible link between duration of action and dissociation rate from receptor. European Journal of Pharmacology. 757: 42-52. PMID 25797281 DOI: 10.1016/j.ejphar.2015.03.009  1
2014 Nishiyama K, Hirai K. The melatonin agonist ramelteon induces duration-dependent clock gene expression through cAMP signaling in pancreatic INS-1 β-cells. Plos One. 9: e102073. PMID 25013953 DOI: 10.1371/journal.pone.0102073  1
2014 Nishiyama K, Nishikawa H, Kato K, Miyamoto M, Tsukamoto T, Hirai K. Pharmacological characterization of M-II, the major human metabolite of ramelteon. Pharmacology. 93: 197-201. PMID 24923230 DOI: 10.1159/000362459  1
2011 Fujimoto T, Kunitomo J, Tomata Y, Nishiyama K, Nakashima M, Hirozane M, Yoshikubo S, Hirai K, Marui S. Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 21: 6414-6. PMID 21917455 DOI: 10.1016/j.bmcl.2011.08.093  1
2011 Koike T, Takai T, Hoashi Y, Nakayama M, Kosugi Y, Nakashima M, Yoshikubo S, Hirai K, Uchikawa O. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands. Journal of Medicinal Chemistry. 54: 4207-18. PMID 21568291 DOI: 10.1021/jm200385u  1
2011 Koike T, Hoashi Y, Takai T, Nakayama M, Yukuhiro N, Ishikawa T, Hirai K, Uchikawa O. 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MTâ‚‚-selective agonists. Journal of Medicinal Chemistry. 54: 3436-44. PMID 21473625 DOI: 10.1021/jm200221q  1
2010 Hirai K, Kato K, Nishikawa H, Yukuhiro N, Nishiyama K, Miyamoto M. [Preclinical pharmacological profiles and clinical outcome of the novel melatonin-receptor agonist ramelteon (Rozerem 8 mg).]. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 136: 51-60. PMID 20628215 DOI: JST.JSTAGE/fpj/136.51  1
2009 Nishiyama K, Shintani Y, Hirai K, Yoshikubo S. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon. The Journal of Pharmacology and Experimental Therapeutics. 330: 855-63. PMID 19556449 DOI: 10.1124/jpet.109.155283  1
2006 Nunomura A, Honda K, Takeda A, Hirai K, Zhu X, Smith MA, Perry G. Oxidative damage to RNA in neurodegenerative diseases. Journal of Biomedicine & Biotechnology. 2006: 82323. PMID 17047315 DOI: 10.1155/JBB/2006/82323  1
2006 Zhu X, Perry G, Moreira PI, Aliev G, Cash AD, Hirai K, Smith MA. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. Journal of Alzheimer's Disease : Jad. 9: 147-53. PMID 16873962  1
2005 Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 48: 301-10. PMID 15695169 DOI: 10.1016/j.neuropharm.2004.09.007  1
2005 Hirai K, Kita M, Ohta H, Nishikawa H, Fujiwara Y, Ohkawa S, Miyamoto M. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. Journal of Biological Rhythms. 20: 27-37. PMID 15654068 DOI: 10.1177/0748730404269890  1
2004 Miyamoto M, Nishikawa H, Doken Y, Hirai K, Uchikawa O, Ohkawa S. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep. 27: 1319-25. PMID 15586784  1
2003 Tateyama M, Takeda A, Onodera Y, Matsuzaki M, Hasegawa T, Nunomura A, Hirai K, Perry G, Smith MA, Itoyama Y. Oxidative stress and predominant Abeta42(43) deposition in myopathies with rimmed vacuoles. Acta Neuropathologica. 105: 581-5. PMID 12734664 DOI: 10.1007/s00401-003-0685-2  1
2002 Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, Avila J, Wataya T, Shimohama S, Atwood CS, Smith MA. Reactive oxygen: its sources and significance in Alzheimer disease. Journal of Neural Transmission. Supplementum. 69-75. PMID 12456052  1
2002 Perry G, Nunomura A, Hirai K, Zhu X, Pérez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM, Takeda A, Smith MA. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radical Biology & Medicine. 33: 1475-9. PMID 12446204 DOI: 10.1016/S0891-5849(02)01113-9  1
2002 Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, Cash AD, Obrenovich ME, Perry G, Smith MA. Role of mitochondrial dysfunction in Alzheimer's disease. Journal of Neuroscience Research. 70: 357-60. PMID 12391597 DOI: 10.1002/jnr.10389  1
2002 Uchikawa O, Fukatsu K, Tokunoh R, Kawada M, Matsumoto K, Imai Y, Hinuma S, Kato K, Nishikawa H, Hirai K, Miyamoto M, Ohkawa S. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. Journal of Medicinal Chemistry. 45: 4222-39. PMID 12213063 DOI: 10.1021/jm0201159  1
2002 Fukatsu K, Uchikawa O, Kawada M, Yamano T, Yamashita M, Kato K, Hirai K, Hinuma S, Miyamoto M, Ohkawa S. Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists. Journal of Medicinal Chemistry. 45: 4212-21. PMID 12213062 DOI: 10.1021/jm020114g  1
2002 Smith MA, Drew KL, Nunomura A, Takeda A, Hirai K, Zhu X, Atwood CS, Raina AK, Rottkamp CA, Sayre LM, Friedland RP, Perry G. Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochemistry International. 40: 527-31. PMID 11850109 DOI: 10.1016/S0197-0186(01)00123-1  1
2001 Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. Journal of Neuropathology and Experimental Neurology. 60: 759-67. PMID 11487050  1
2001 Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, et al. Mitochondrial abnormalities in Alzheimer's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 3017-23. PMID 11312286  1
2000 Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. Journal of Neuropathology and Experimental Neurology. 59: 1011-7. PMID 11089579  1
2000 Rottkamp CA, Nunomura A, Hirai K, Sayre LM, Perry G, Smith MA. Will antioxidants fulfill their expectations for the treatment of Alzheimer disease? Mechanisms of Ageing and Development. 116: 169-79. PMID 10996017 DOI: 10.1016/S0047-6374(00)00124-X  1
2000 Perry G, Nunomura A, Hirai K, Takeda A, Aliev G, Smith MA. Oxidative damage in Alzheimer's disease: the metabolic dimension. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 18: 417-21. PMID 10817925 DOI: 10.1016/S0736-5748(00)00006-X  1
1999 Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Annals of the New York Academy of Sciences. 893: 362-4. PMID 10672267  1
1999 Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 1959-64. PMID 10066249  1
1999 Smith MA, Hirai K, Nunomura A, Perry G. Mitochondrial abnormalities: A primary basis for oxidative damage in Alzheimer's disease Drug Development Research. 46: 26-33.  1
1998 Perry G, Castellani RJ, Hirai K, Smith MA. Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. Journal of Alzheimer's Disease : Jad. 1: 45-55. PMID 12214011  1
1998 Hirai K, Hayako H, Kato K, Miyamoto M. Idebenone protects hippocampal neurons against amyloid β-peptide- induced neurotoxicity in rat primary cultures Naunyn-Schmiedeberg's Archives of Pharmacology. 358: 582-585. PMID 9840428  1
1998 Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. Journal of Neurochemistry. 70: 2212-5. PMID 9572310  1
1997 Hirai K, Kato K, Nakayama T, Hayako H, Ishihara Y, Goto G, Miyamoto M. Neurochemical effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1(2,3,4,5- tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats Journal of Pharmacology and Experimental Therapeutics. 280: 1261-1269. PMID 9067312  1
1996 Ohta H, Nishikawa H, Hirai K, Kato K, Miyamoto M. Relationship of impaired brain glucose metabolism to learning deficit in the senescence-accelerated mouse Neuroscience Letters. 217: 37-40. PMID 8905734 DOI: 10.1016/0304-3940(96)13064-0  1
1996 Miyamoto M, Takahashi H, Kato K, Hirai K, Ishihara Y, Goto G. Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H- 1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models Journal of Pharmacology and Experimental Therapeutics. 277: 1292-1304. PMID 8667190  1
1994 Ishihara Y, Hirai K, Miyamoto M, Goto G. Central cholinergic agents. 6. Synthesis and evaluation of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- 1-propanones and their analogs as central selective acetylcholinesterase inhibitors Journal of Medicinal Chemistry. 37: 2292-2299. PMID 8057278  1
1992 Hirai K, Miyamoto M, Nagaoka A. Effects of idebenone and other drugs for cerebrovascular disorders on glutamate-induced cell death in N 18-RE-105 cells Japanese Pharmacology and Therapeutics. 20: 31-36.  1
Show low-probability matches.